Liraglutide is also associated with nausea, a side effect that is less dose dependent and declines in frequency within 4 weeks of treatment in most patients (49).
Further, these methods can operate effectively with fewer projections, resulting in less dose exposure to specimens [4, 5].
Owing to concerns about tolerability, there remains a tendency in clinical routine to use less dose-intensive chemotherapy in older patients with the avoidance of those agents perceived to be more toxic.
The better peak-to-entrance ratio and less entrance dose in the region Z = 2 to 8 (i.e. 3He to 16O) may provide the suitability of the ion beams for hadrontherapy.
Two earlier single-centre randomised clinical trials showed a beneficial effect of an intensive CRRT dose when compared with a less-intensive dose in both CVVH (≥ 35 ml/kg/hour versus ≤ 20 ml/kg/hour) [ 4] and CVVHDF (≥ 42 ml/kg/hour versus ≤ 25 ml/kg/hour) [ 7].
Overall, there were no notable differences between the two CZP dosing regimens in the overall axSpA population or either subpopulation, enabling dosing flexibility and the convenience of less frequent dosing in some patients.
However, because of the severe toxicity observed, the use of less toxic doses in combination with other antiproliferative agents, as reported above from in vitro experiments, would be desirable.
The HORIZON trial [ 22] (using a PRN regimen) has shown that continued treatment is needed in a large proportion of patients in the third and fourth year, and that less frequent dosing in years 3 and 4 was associated with visual decline.
Animals dosed with MTX had less of the dose in the liver, and excreted more of the dose via the faeces.
Patients with malignant disease excreted less of the dose in urine, incorporated more into the reduced folate pool, and showed decreased catabolism of folate, when compared to controls.
